Docket No: AHP-98396 Patent

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

Claims 1-4 (canceled).

Claim 5 (original): A method of treating or inhibiting hyperproliferative vascular disorders in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formula I having the structure

wherein

- R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are each, independently, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, benzoyl, or -SO<sub>3</sub>H;
- R<sup>9</sup> is hydrogen, CN, NO<sub>2</sub>, halo, CF<sub>3</sub>, alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms;
- $R^{10}$  is hydrogen, -NO<sub>2</sub>, -NHR<sup>11</sup>, -NHR<sup>13</sup>, -N(R<sup>13</sup>)<sub>2</sub>, -NCH<sub>3</sub>R<sup>13</sup>, -NHCO<sub>2</sub>alkyl, wherein the alkyl moiety contains 1-6 carbon atoms, alkylsulfonamide of 1 to 4 carbon atoms,

$$-\frac{1}{2}-NH$$

Z is O or S;

- $R^{11}$  is an  $\alpha$ -amino acid in which the  $\alpha$  carboxyl group forms an amide with the nitrogen of  $R^{10}$ , wherein if said amino acid is glutamic acid or aspartic acid, the non- $\alpha$  carboxylic acid is an alkyl ester in which the alkyl moiety contains from 1-6 carbon atoms;
- R<sup>12</sup> is hydrogen, CN, NO<sub>2</sub>, halo, CF<sub>3</sub>, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or benzoyl;

Docket No: AHP-98396
Patent

R<sup>13</sup> is hydrogen, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl;

or a pharmaceutically acceptable salt thereof.

Claim 6 (original): A method of treating or inhibiting restenosis in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formula I having the structure

wherein

- R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are each, independently, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, benzoyl, or -SO<sub>3</sub>H;
- $R^9$  is hydrogen, CN,  $NO_2$ , halo,  $CF_3$ , alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms;
- R<sup>10</sup> is hydrogen, -NO<sub>2</sub>, -NHR<sup>11</sup>, -NHR<sup>13</sup>, -N(R<sup>13</sup>)<sub>2</sub>, -NCH<sub>3</sub>R<sup>13</sup>, -NHCO<sub>2</sub>alkyl, wherein the alkyl moiety contains 1-6 carbon atoms, alkylsulfonamide of 1 to 4 carbon atoms,

$$-\frac{1}{2}-NH$$

$$-\frac{1}{2}-NH$$

$$-\frac{1}{2}-NH$$

$$-\frac{1}{2}-NH$$

$$-\frac{1}{2}-NH$$

$$-\frac{1}{2}-NH$$

$$-\frac{1}{2}-NH$$

$$-\frac{1}{2}-NH$$

$$-\frac{1}{2}-NH$$

Z is O or S;

- $R^{11}$  is an  $\alpha$ -amino acid in which the  $\alpha$  carboxyl group forms an amide with the nitrogen of  $R^{10}$ , wherein if said amino acid is glutamic acid or aspartic acid, the non- $\alpha$  carboxylic acid is an alkyl ester in which the alkyl moiety contains from 1-6 carbon atoms;
- R<sup>12</sup> is hydrogen, CN, NO<sub>2</sub>, halo, CF<sub>3</sub>, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or benzoyl;
- R<sup>13</sup> is hydrogen, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl;

Docket No: AHP-98396

Patent

or a pharmaceutically acceptable salt thereof.

Claim 7 (original): The method according to claim 6, wherein the restenosis results from a vascular angioplasty procedure, vascular reconstructive surgery, or organ or tissue transplantation.

Claim 8 (original): A method of inhibiting angiogenesis in a malignant tumor, sarcoma, or neoplastic tissue in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of formula I having the structure

wherein

- R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are each, independently, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, benzoyl, or -SO<sub>3</sub>H;
- $R^9$  is hydrogen, CN,  $NO_2$ , halo,  $CF_3$ , alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms;
- R<sup>10</sup> is hydrogen, -NO<sub>2</sub>, -NHR<sup>11</sup>, -NHR<sup>13</sup>, -N(R<sup>13</sup>)<sub>2</sub>, -NCH<sub>3</sub>R<sup>13</sup>, -NHCO<sub>2</sub>alkyl, wherein the alkyl moiety contains 1-6 carbon atoms, alkylsulfonamide of 1 to 4 carbon atoms,

$$- \left\{-NH\right\} - \left\{$$

Z is O or S;

- $R^{11}$  is an  $\alpha$ -amino acid in which the  $\alpha$  carboxyl group forms an amide with the nitrogen of  $R^{10}$ , wherein if said amino acid is glutamic acid or aspartic acid, the non- $\alpha$  carboxylic acid is an alkyl ester in which the alkyl moiety contains from 1-6 carbon atoms;
- R<sup>12</sup> is hydrogen, CN, NO<sub>2</sub>, halo, CF<sub>3</sub>, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or benzoyl;

Docket No: AHP-98396

Patent

R<sup>13</sup> is hydrogen, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl;

or a pharmaceutically acceptable salt thereof.

Claim 9 (canceled).